Agios Pharmaceuticals, Inc.
AGIOAgios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 2 past
Tebapivat Phase 2 Results Expected
Primary completion for Tebapivat trial (NCT06924970) in Sickle Cell Disease
SourcePyruvate Kinase Deficiency
2 drugs in this indication
Sickle Cell Disease
2 drugs in this indication
Myelodysplastic Syndromes
1 drug in this indication
Non-Transfusion-dependent Alpha-Thalassemia
1 drug in this indication
Pediatric Pyruvate Kinase Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)